Astellas Continues Gene and Cell Therapy Acquisition Trend with Xyphos Buy
By Jawala Prasad
Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)
Published: 28 Jan-2020
DOI: 10.3833/pdr.v2020.i1.2503 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In its second gene and cell therapy purchase in less than a month, Astellas Pharma has acquired immuno-oncology specialist Xyphos Biosciences in a deal worth up to US$665 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018